What this pack is
ZYLOPRIM is the brand name in this record; allopurinol is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
ZYLOPRIMGeneric nameallopurinol
How this medicine works
The current ZYLOPRIM label describes allopurinol as a xanthine-oxidase inhibitor and explains that the enzyme participates in conversion of hypoxanthine and xanthine to uric acid; its metabolite oxypurinol also inhibits the enzyme. This explains a drug-action pathway, not gout, stones, joint pain or another symptom, and it does not decide individual suitability, tablet count, initiation, combination or switching.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- ZYLOPRIM
- Generic name
- allopurinol
- Dosage-form class
- Oral tablets: 100 mg, 200 mg and 300 mg (as listed in the current U.S. label; this dossier separately displays three 90-tablet bottle panels)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Prescribing information revised Jan 2025; DailyMed SPL v10
100 mg per tablet; 90-tablet bottle
- Product code
- NDC 70199-031-90
- Form and route
- ZYLOPRIM allopurinol oral tablet · oral
- Container
- bottle
- allopurinol
- 100 mglabelled amount per tablet; not an individual's tablet count, start, adjustment or switching rule
- Package
- 90 tablets per bottle
- Labelled appearance
- white to off-white · beveled raised hexagonal tablet · imprint ZYLOPRIM 100Labelled as functionally scored; verify the exact current label before any handling
United States label · Prescribing information revised Jan 2025; DailyMed SPL v10
200 mg per tablet; 90-tablet bottle
- Product code
- NDC 70199-032-90
- Form and route
- ZYLOPRIM allopurinol oral tablet · oral
- Container
- bottle
- allopurinol
- 200 mglabelled amount per tablet; not an individual's tablet count, start, adjustment or switching rule
- Package
- 90 tablets per bottle
- Labelled appearance
- white to off-white · biconvex round tablet · imprint ZYLOPRIM / 200Labelled as functionally scored; verify the exact current label before any handling
United States label · Prescribing information revised Jan 2025; DailyMed SPL v10
300 mg per tablet; 90-tablet bottle
- Product code
- NDC 70199-033-90
- Form and route
- ZYLOPRIM allopurinol oral tablet · oral
- Container
- bottle
- allopurinol
- 300 mglabelled amount per tablet; not an individual's tablet count, start, adjustment or switching rule
- Package
- 90 tablets per bottle
- Labelled appearance
- peach · beveled raised hexagonal tablet · imprint ZYLOPRIM 300Labelled as functionally scored; verify the exact current label before any handling
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
ZYLOPRIM label reading: 100, 200 and 300 mg plus scoring identify a tablet; they do not answer “how many tablets”
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the current U.S. DailyMed public label to check ZYLOPRIM, allopurinol, labelled amount per tablet, exact NDC, 90-tablet bottle, tablet appearance and target market. It provides no individual tablet count, initiation, increase, missed-use remedy, splitting, stopping, combination or switching plan.
- Check ZYLOPRIM, allopurinol, 100/200/300 mg, the actual NDC, oral-tablet form and target market together. Milligrams are the labelled amount in this exact tablet, not an answer to how many tablets anyone should take; a shared generic name, another strength or another dosage form cannot be self-converted from a number.
- The current label describes shape, imprint and functional scoring for the three tablet presentations. These are product-identity clues, not a way to authenticate a photograph or permission to self-split, make up or adjust use. If the actual pack, prescription or swallowing situation differs, take the pack to a pharmacist or prescribing team.
- The label links HLA-B*58:01 with risk of severe allopurinol hypersensitivity and explains that the meaning of testing depends on timing around treatment and population context. This page neither recommends universal screening nor turns a positive, negative or existing genetic report into a conclusion about starting, continuing, stopping or switching; take the original report, actual pack and complete medicine list to a professional.
- The current label flags thiazide diuretics, ampicillin, amoxicillin, azathioprine and mercaptopurine among co-medications requiring particular review. It is not a checklist for self-stopping, adding, spacing or switching products; give prescription medicines, OTC products, supplements and recent changes together to a pharmacist or clinician. With a new rash, blisters, mouth/eye discomfort, fever, lip/facial swelling, breathing difficulty or another acute severe concern, prioritise local urgent medical and prescribing-team pathways rather than self-managing from a webpage or self-restarting treatment.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. ZYLOPRIM allopurinol public label (Casper Pharma; revised Jan 2025, SPL v10) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about ZYLOPRIM (allopurinol). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
ZYLOPRIM is the brand in this record and allopurinol is the active-ingredient name. Check both with the dosage form (Oral tablets: 100 mg, 200 mg and 300 mg (as listed in the current U.S. label; this dossier separately displays three 90-tablet bottle panels)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How allopurinol works: it affects xanthine oxidase in a uric-acid production pathway
- “Affects a uric-acid production pathway” does not mean every joint pain, redness, stone, laboratory number or other symptom has the same cause, or that a webpage can decide whether allopurinol is needed. Diagnosis, tests, kidney context, the complete medicine list and the exact product label must be considered together by a professional.
- A product that also affects uric acid, purines or xanthine oxidase, or whose name includes similar words, does not prove that products can be self-combined, alternated, milligram-converted or replaced from one pack to another. Brand, strength, dosage form, market and co-medications require item-by-item review.
- Mechanism cannot decide genetic testing, diet, fluid intake, testing frequency, treatment duration, whether to stop or how to handle missed use. If a genetic or laboratory report already exists, discuss whether it relates to the current prescription with a pharmacist or clinician using the original materials, actual bottle and complete medicine list.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
SOURCE-TRACEABLE ARCHIVE
ZYLOPRIMallopurinol
This page links to public primary-source material for ZYLOPRIM. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the current label
The current ZYLOPRIM label lists Initial U.S. Approval: 1966. This year locates this U.S. public-label archive only; it does not establish approval, supply, sale eligibility, originator/generic relationship or individual suitability in Mainland China, the EU, Japan or another market.
DailyMed (NLM): current U.S. ZYLOPRIM allopurinol public label (Casper Pharma; revised Jan 2025, SPL v10) ↗Current label effective date and SPL v10
The current ZYLOPRIM label page lists a Jan 2025 revision, effective time 9 Jan 2025 and Version 10. This page separately displays 90-tablet bottle panels for 100 mg, 200 mg and 300 mg; it does not establish actual availability, stock, individual tablet count, splitting, initiation, stopping, co-use or switching.
DailyMed (NLM): current U.S. ZYLOPRIM allopurinol public label (Casper Pharma; revised Jan 2025, SPL v10) ↗
MARKET SCOPE
Market-record boundary
United States
Current public label and three exact 90-tablet bottle panels linkedThe panels correspond respectively to NDC 70199-031-90 (100 mg), NDC 70199-032-90 (200 mg) and NDC 70199-033-90 (300 mg). They do not authenticate a product or establish actual availability, stock, individual tablet count, splitting, initiation, stopping, co-use or interchangeability.
Mainland China, EU, Japan and other markets
Market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the U.S. label, NDC or brand name; every market version needs separate checking against current local regulatory information.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Do ZYLOPRIM 100, 200 or 300 mg tablets, or a scored tablet, mean that they can be self-split, adjusted or exchanged between packs?
No. Milligrams, shape, imprint and functional scoring are label-identity information for an exact tablet, not rules for individual tablet count, splitting, make-up use, initiation, stopping or switching. Take the actual bottle, prescription and complete medicine list to a pharmacist or prescribing team for review.
Does the HLA-B*58:01 information mean that everyone should be screened, or that a report can be used to self-start or stop allopurinol?
No. The current label links this marker with severe hypersensitivity risk, but whether testing is relevant requires professional assessment of treatment stage, population context, kidney function, prior reactions, complete medicine list and the exact prescription. This page does not recommend universal screening or use any report in place of clinical review.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.